Ark ETF Trust NPORT-P ARK Genomic Revolution ETF (Oct 2024 report)

Schedule of Investments

ARK Genomic Revolution ETF

October 31, 2024 (Unaudited)

Investments	Shares		Value
COMMON STOCKS–99.7%
Biotechnology - 67.8%
Absci Corp.*†		7,608,721	$	29,217,488
Amgen, Inc.		74,334		23,798,773
Arcturus Therapeutics Holdings, Inc.*†		2,038,675		36,145,708
Beam Therapeutics, Inc.*		1,892,997		41,475,564
CareDx, Inc.*†		2,696,491		59,673,346
Compass Pathways PLC (United Kingdom)*(a)		1,946,030		9,263,103
CRISPR Therapeutics AG (Switzerland)*		1,781,658		82,651,115
Exact Sciences Corp.*		219,870		15,155,639
Incyte Corp.*		205,176		15,207,645
Intellia Therapeutics, Inc.*		3,083,985		43,854,267
Ionis Pharmaceuticals, Inc.*		1,343,141		51,563,183
Moderna, Inc.*		237,218		12,895,171
Natera, Inc.*		364,343		44,070,929
Nurix Therapeutics, Inc.*		2,019,171		49,631,223
Prime Medicine, Inc.*		2,739,043		10,627,487
Recursion Pharmaceuticals, Inc., Class A*		12,816,224		80,998,536
Regeneron Pharmaceuticals, Inc.*		14,710		12,329,922
Repare Therapeutics, Inc. (Canada)*†		2,435,100		8,157,585
Senti Biosciences, Inc.*		168,235		365,070
Twist Bioscience Corp.*		2,437,872		98,392,514
Veracyte, Inc.*		1,608,228		54,261,613
Vertex Pharmaceuticals, Inc.*		40,079		19,076,802
Total Biotechnology				798,812,683
Electronic Equipment, Instruments & Components - 0.8%
908 Devices, Inc.*†		3,125,257		9,797,681
Health Care Equipment & Supplies - 2.4%
Butterfly Network, Inc.*		8,418,016		14,984,068
Cerus Corp.*		8,208,021		12,886,593
Total Health Care Equipment & Supplies				27,870,661
Health Care Providers & Services - 4.1%
Accolade, Inc.*†		5,223,950		16,559,921
Guardant Health, Inc.*		1,467,771		32,114,829
Total Health Care Providers & Services				48,674,750
Health Care Technology - 5.5%
Schrodinger, Inc.*		2,267,514		39,896,909
Veeva Systems, Inc., Class A*		120,722		25,210,375
Total Health Care Technology				65,107,284
Life Sciences Tools & Services - 19.1%
10X Genomics, Inc., Class A*		2,789,313		44,712,687
Adaptive Biotechnologies Corp.*†		11,255,993		54,479,006
Illumina, Inc.*		41,962		6,048,403
Pacific Biosciences of California, Inc.*		12,389,944		26,886,178
Personalis, Inc.*†		6,875,216		34,719,841
Quantum-Si, Inc.*†		11,497,793		8,059,953
Standard BioTools, Inc.*		6,975,605		13,672,186
Tempus AI, Inc.*		789,319		35,219,414
Total Life Sciences Tools & Services				223,797,668
Total Common Stocks
(Cost $3,458,221,878)				1,174,060,727
MONEY MARKET FUND–0.1%
Goldman Sachs Financial Square Treasury Obligations Fund, 4.74% (b)
(Cost $1,750,786)		1,750,786		1,750,786
Total Investments–99.8%
(Cost $3,459,972,664)				1,175,811,513
Other Assets in Excess of Liabilities–0.2%				2,768,505
Net Assets–100.0%			$	1,178,580,018

† Affiliated security

* Non-income producing security

(a) American Depositary Receipt

(b) Rate shown represents annualized 7-day yield as of October 31, 2024.

Schedule of Investments (continued)

ARK Genomic Revolution ETF

October 31, 2024 (Unaudited)

Affiliated Issuer Transactions

An affiliated company is a company in which the Fund has ownership of at least 5% of the voting securities, or a company that is under common ownership or control. Period-to-date transactions with companies which are or were affiliates are as follows:

	Value ($) at 7/31/2024		Purchases Cost ($)		Sales Proceeds ($)			Net Realized Gain/(Loss) ($)			Net Change in Unrealized Appreciation (Depreciation) ($)			Dividend Income ($)		Capital Gain Distributions ($)		Number of Shares at 10/31/2024		Value ($) at 10/31/2024
Common Stocks — 21.8%
Biotechnology — 11.3%
Absci Corp.
		24,990,376		16,182,821		(8,184,563	)		1,386,881			(5,158,027	)		–		–		7,608,721		29,217,488
Arcturus Therapeutics Holdings, Inc.
		45,569,126		16,017,288		(14,074,340	)		174,930			(11,541,296	)		–		–		2,038,675		36,145,708
CareDx, Inc.
		97,345,523		22,801,876		(81,078,963	)		(78,109,451	)		98,714,361			–		–		2,696,491		59,673,346
Repare Therapeutics, Inc.
		9,725,317		2,175,839		(2,678,780	)		(1,802,820	)		738,029			–		–		2,435,100		8,157,585
Electronic Equipment, Instruments & Components — 0.8%
908 Devices, Inc.
		22,657,608		3,564,965		(6,929,837	)		(37,300,632	)		27,805,577			–		–		3,125,257		9,797,681
Health Care Equipment & Supplies — 0.0%
Butterfly Network, Inc.  ^
		11,946,968		3,800,753		(7,691,060	)		(29,921,002	)		36,848,409			–		–		8,418,016		14,984,068
Health Care Providers & Services — 1.4%
Accolade, Inc.
		22,871,518		5,463,999		(6,866,228	)		(3,241,216	)		(1,668,152	)		–		–		5,223,950		16,559,921
Life Sciences Tools & Services — 8.3%
Adaptive Biotechnologies Corp.
		54,689,649		14,401,381		(17,802,757	)		1,659,602			1,531,131			–		–		11,255,993		54,479,006
Personalis, Inc.
		22,038,148		14,524,518		(11,431,343	)		3,677,709			5,910,809			–		–		6,875,216		34,719,841
Quantum-Si, Inc.
		13,382,946		2,796,087		(3,468,759	)		(1,492,747	)		(3,157,574	)		–		–		11,497,793		8,059,953
	$	325,217,179	$	101,729,527	$	(160,206,630	)	$	(144,968,746	)	$	150,023,267		$	–	$	–		61,175,212	$	271,794,597

^ As of October 31, 2024, the company was no longer considered to be an affiliated security.

Fair Value Measurement

The Fund discloses the fair value of its investments in a hierarchy that distinguishes between: (i) market participant assumptions developed based on market data obtained from sources independent of the Fund (observable inputs) and (ii) the Fund’s own assumptions about market participant assumptions developed based on the best information available under the circumstances (unobservable inputs). The three levels defined by the hierarchy are as follows:

• Level 1 — Quoted prices in active markets for identical assets.

• Level 2 — Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.).

• Level 3 — Significant unobservable inputs (including each Fund’s own assumptions in determining the fair value of investments).

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following is a summary of the valuations as of October 31, 2024, based upon the three levels defined above:

ARK Genomic Revolution ETF	Level 1		Level 2		Level 3		Total
Assets
Common Stocks‡	$	1,174,060,727	$	–	$	–	$	1,174,060,727
Money Market Fund		1,750,786		–		–		1,750,786
Total	$	1,175,811,513	$	–	$	–	$	1,175,811,513

‡ Please refer to the Schedule of Investments to view securities segregated by industry type.